nach oben

Urolithiasis

Erschienen in:

01.08.2009 | Review

Genetic basis of renal cellular dysfunction and the formation of kidney stones

verfasst von: Saeed R. Khan, Benjamin K. Canales

Erschienen in: Urolithiasis | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Nephrolithiasis is a result of formation and retention of crystals within the kidneys. The driving force behind crystal formation is urinary supersaturation with respect to the stone-forming salts, which means that crystals form when the concentrations of participating ions are higher than the thermodynamic solubility for that salt. Levels of supersaturation are kept low and under control by proper functioning of a variety of cells including those that line the renal tubules. It is our hypothesis that crystal deposition, i.e., formation and retention in the kidneys, is a result of impaired cellular function, which may be intrinsic and inherent or triggered by external stimuli and challenges. Cellular impairment or dysfunction affects the supersaturation, by influencing the excretion of participating ions such as calcium, oxalate and citrate and causing hypercalciuria, hyperoxaluria or hypocitraturia. The production and excretion of macromolecular promoters and inhibitors of crystallization is also dependent upon proper functioning of the renal epithelial cells. Insufficient or ineffective crystallization modulators such as osteopontin, Tamm-Horsfall protein, bikunin, etc. are most likely produced by the impaired cells.

Stamatelou KK, Francis MF, Jones CA, Curhan GC (2003) Time trends in reported prevalence of kidney stones in the United States: 1976–1994. Kidney Int 63:1817–1823. doi:10.1046/j.1523-1755.2003.00917.x PubMedCrossRef

Randall A (1940) The etiology of primary renal calculus. Int Abstr Surg 71:209–240

Finlayson B, Reid S (1978) The expectation of free or fixed particles in urinary stone disease. Invest Urol 15:442–448PubMed

Kok DJ, Khan SR (1994) Calcium oxalate nephrolithiasis, a free or fixed particle disease. Kidney Int 46:847–854. doi:10.1038/ki.1994.341 PubMedCrossRef

Kavanagh JP (1995) Calcium oxalate crystallization in vitro. In: Khan SR (ed) Calcium oxalate in biological systems. CRC Press, Boca Raton, p 1

Robertson WG, Peacock M, Nordin BEC (1968) Activity products in stone forming and non-stone forming urine. Clin Sci 34:579–594

Khan SR, Kok DJ (2004) Modulators of urinary stone formation. Front Biosci 9:1450–1480. doi:10.2741/1347 PubMedCrossRef

Vezzoli G, Soldati L, Gambaro G (2008) Update on primary hypercalciuria from a genetic perspective. J Urol 179:1676–1682. doi:10.1016/j.juro.2008.01.011 PubMedCrossRef

Geng W, Wang Z, Zhang J, Reed BY, Pak CY, Moe OW (2005) Cloning and characterization of the human soluble adenylyl cyclase. Am J Physiol Cell Physiol 288:C1305–C1311. doi:10.1152/ajpcell.00584.2004 PubMedCrossRef

10.

Pastor-Soler N, Beaulieu V, Litvin TN, Da Silva N, Chen Y, Brown D, Buck J, Levin LR, Breton S (2003) Bicarbonate-regulated adenylyl cyclase (sAC) is a sensor that regulates pH-dependent V-ATPase recycling. J Biol Chem 278:49523–49529. doi:10.1074/jbc.M309543200 PubMedCrossRef

11.

Reed BY, Heller HJ, Gitomer WL, Pak CY (1999) Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23.3-q24. J Clin Endocrinol Metab 84:3907–3911. doi:10.1210/jc.84.11.3907 PubMedCrossRef

12.

Reed BY, Gitomer WL, Heller HJ, Hsu MC, Lemke M, Padalino P et al (2002) Identification and characterization of a gene with base substitutions associated with the absorptive hypercalciuria phenotype and low spine bone density. J Clin Endocrinol Metab 87:1476–1481. doi:10.1210/jc.87.4.1476 PubMedCrossRef

13.

Bushinsky DA (1999) Genetic hypercalciuric stone-forming rats. Curr Opin Nephrol Hypertens 8:479–489. doi:10.1097/00041552-199907000-00013 PubMedCrossRef

14.

Khullar M, Relan V, Singh SK (2006) VDR gene and urinary calcium excretion in nephrolithiasis. Kidney Int 69:943–951. doi:10.1038/sj.ki.5000176 PubMedCrossRef

15.

Recker F, Rubben H, Bex A, Constantinides C (1989) Morphological changes following ESWL in the rat kidney. Urol Res 17:229–233PubMed

16.

Relan V, Khullar M, Singh SK, Sharma SK (2004) Association of vitamin D receptor genotypes with calcium excretion in nephrolithiatic subjects in northern India. Urol Res 32:236–241. doi:10.1007/s00240-004-0414-x PubMedCrossRef

17.

Rendina D, Mossetti G, Viceconti R, Sorrentino M, Castaldo R, Manno G et al (2004) Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stone-forming patients. Urology 64:838–842. doi:10.1016/j.urology.2004.05.013 CrossRef

18.

Soylemezoglu O, Ozkaya O, Gonen S, Misirlioglu M, Kalman S, Buyan N (2004) Vitamin D receptor gene polymorphism in hypercalciuric children. Pediatr Nephrol 19:724–730. doi:10.1007/s00467-004-1490-4 PubMedCrossRef

19.

Bushinsky DA, Asplin JR, Grynpass MD et al (2002) Calcium oxalate stone formation in genetic hypercalciuric stone-forming rats. Kidney Int 61:975–987. doi:10.1046/j.1523-1755.2002.00190.x PubMedCrossRef

20.

Zerwekh JE, Hughes MR, Reed BY, Breslau NA, Heller HJ, Lemke M et al (1995) Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive hypercalciuria. J Clin Endocrinol Metab 80:2960–2965. doi:10.1210/jc.80.10.2960 PubMedCrossRef

21.

Scott P, Ouimet D, Valiquette L, Guay G, Proulx Y, Trouve ML et al (1999) Suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc Nephrol 10:1007–1013PubMed

22.

Muller D, Hoenderop JG, Vennekens R, Eggert P, Harangi F, Mehes K et al (2002) Epithelial Ca(2−) channel (ECAC1) in autosomal dominant idiopathic hypercalciuria. Nephrol Dial Transplant 17:1614–1621. doi:10.1093/ndt/17.9.1614 PubMedCrossRef

23.

Bid HK, Kumar A, Kapoor R, Mittal RD (2005) Association of vitamin D receptor- gene (FokI) polymorphism with calcium oxalate nephrolithiasis. J Endourol 19:111–115. doi:10.1089/end.2005.19.111 PubMedCrossRef

24.

Chen W-C, Chen H-Y, Lu H-F, Hsu C-D, Tsai F-J (2001) Association of the vitamin D receptor gene start codon Fok I polymorphism with calcium oxalate stone disease. BJU Int 87:168–174. doi:10.1046/j.1464-410x.2001.02074.x PubMedCrossRef

25.

Nishijima S, Sugaya K, Naito A, Morozumi M, Hatano T, Ogawa Y (2002) Association of vitamin D receptor gene polymorphism with urolithiasis. J Urol 167:2188–2195. doi:10.1016/S0022-5347(05)65126-9 PubMedCrossRef

26.

Ozkaya O, Soylemezoglu O, Misirlioglu M, Gonen S, Buyan N, Hasanoglu E (2003) Polymorphisms in the vitamin D receptor gene and the risk of calcium nephrolithiasis in children. Eur Urol 44:150–154. doi:10.1016/S0302-2838(03)00206-9 PubMedCrossRef

27.

Devuyst O, Pirson Y (2007) Genetics of hypercalciuric stone forming diseases. Kidney Int 72:1065–1072. doi:10.1038/sj.ki.5002441 PubMedCrossRef

28.

Tfelt-Hansen J, Brown EM (2004) The calcium-sensing receptor in normal physiology and pathophysiology: a review. Crit Rev Clin Lab Sci 42:35–48. doi:10.1080/10408360590886606 CrossRef

29.

Vezzoli G, Tanini A, Ferrucci L, Soldati L, Bianchin C, Franceschelli F et al (2002) Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol 13:2125–2517. doi:10.1097/01.ASN.0000030077.72157.D2 CrossRef

30.

Vezzoli G, Terranegra A, Arcidiacono T, Biasion R, Coviello D, Syren ML et al (2007) R990G polymorphism of calcium-sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int 71:1155–1163. doi:10.1038/sj.ki.5002156 PubMedCrossRef

31.

Hough TA, Bogani D, Cheeseman MT, Favor J, Nesbit MA, Thakker RV, Lyon MF (2004) Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification. Proc Natl Acad Sci USA 101:13566–13571. doi:10.1073/pnas.0405516101 PubMedCrossRef

32.

Prie D, Huart V, Bakouh N, Planelles G, Dellis O, Gerard B et al (2002) Nephrolithiasis and osteoporosis caused by mutations in the type 2a sodium-phosphate cotransporter. N Engl J Med 347:983–988. doi:10.1056/NEJMoa020028 PubMedCrossRef

33.

Lapointe Y, Tessier J, Paquette Y, Wallendorff B, Coady MJ, Pichette V et al (2006) NPT2 gene variation in calcium nephrolithiasis with renal phosphate leak. Kidney Int 69:226–233. doi:10.1038/sj.ki.5000437 CrossRef

34.

Bergwitz C, Roslin NM, Tieder M, Loredo-Osti JC, Bastepe M, Abu-Zahra H, Frappier D, Burkett K, Carpenter TO, Anderson D, Garabedian M, Sermet I, Fujiwara TM, Morgan K, Tenenhouse HS, Juppner H (2006) SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-Iic in maintaining phosphate homeostasis. Am J Hum Genet 78:179–192. doi:10.1086/499409 PubMedCrossRef

35.

Tennenhouse HS (2005) Regulation of phosphorus homeostasis by the type iia Na/phosphate cotransporter. Annu Rev Nutr 25:197–214. doi:10.1146/annurev.nutr.25.050304.092642 CrossRef

36.

Khan SR, Glenton PA (2008) Calcium oxalate crystal deposition in kidneys of hypercalciuric mice with disrupted type IIa sodium-phosphate cotransporter. Am J Physiol Renal Physiol 294:F1109–F1115. doi:10.1152/ajprenal.00620.2007 PubMedCrossRef

37.

Wrong OM, Norden AG, Feest TG (1994) Dent’s disease; a familial proximal renal tubular syndrome with low-molecular weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. QJM 87:473–493PubMed

38.

Christensen EI, Devuyst O, Dom G, Nielsen R, Van der Smissen P, Verroust P et al (2003) Loss of chloride channel ClC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. Proc Natl Acad Sci USA 100:8472–8479. doi:10.1073/pnas.1432873100 PubMedCrossRef

39.

Devuyst O, Jouret F, Auzanneau C, Courtoy PJ (2005) Chloride channels and endocytosis: new insights from Dent’s disease and CIC-5 knockout mice. Nephron Physiol 99:69–73. doi:10.1159/000083210 CrossRef

40.

Piwon N, Gunther W, Schwake M, Bosl MR, Jentsch TJ (2000) ClC-5 Cl- -channel disruption impairs endocytosis in a mouse model for Dent’s disease. Nature 408:369–373. doi:10.1038/35042597 PubMedCrossRef

41.

Gunther W, Piwon N, Jentsch TJ (2003) The ClC-5 chloride channel knock-out mouse-an animal model for Dent’s disease. Pflugers Arch 445:456–462PubMed

42.

Loffing J, Loffing-Cueni D, Valderrabano V, Klausli L, Hebert SC et al (2001) Distribution of transcellular calcium and sodium transport pathways along mouse distal nephron. Am J Physiol Renal Physiol 281:F1021–F1027PubMed

43.

Suzuki Y, Landowski CP, Hedinger MA (2008) Mechanisms and regulation of epithelial Ca absorption in health and disease. Annu Rev Physiol 70:257–271. doi:10.1146/annurev.physiol.69.031905.161003 PubMedCrossRef

44.

Hoenderop JG, van Leeuwen JP, van der Eerden BC et al (2003) Renal Ca₂+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 112:1906–1914PubMed

45.

Jiang Y, Ferguson WB, Peng JB (2006) WNK4 enhances TRPV5-mediated calcium transport: potential role in hypercalciuria of familial hyperkalemic hypertension caused by gene mutation of WNK4. Am J Physiol Renal Physiol 292:F545–F554PubMedCrossRef

46.

Colegio OR, Van Itallie CM, McCrea HJ, Rahner C, Anderson JM (2002) Claudins create charge-selective channels in the paracellular pathway between epithelial cells. Am J Physiol Cell Physiol 283:C142–C147PubMed

47.

Konrad M, Schlingmann KP, Gudermann T (2004) Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol 286:F599–F605. doi:10.1152/ajprenal.00312.2003 PubMedCrossRef

48.

Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Scharer K, Seyberth HW, Konrad M (2001) Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 12:1872–1881PubMed

49.

Muller D, Kausalya PJ, Claverie-Martin F, Meij IC, Eggert P, Garcia-Nieto V, Hunziker W (2003) A novel claudin 16 mutation associated with childhood hypercalciuria abolishes binding to ZO-1 and results in lysosomal mistargeting. Am J Hum Genet 73:1293–1301. doi:10.1086/380418 PubMedCrossRef

50.

Arking DE (2002) Association of human aging with a functional variant of klotho. Proc Natl Acad Sci USA 99:856–861. doi:10.1073/pnas.022484299 PubMedCrossRef

51.

Kuro-o M, Matsumora Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kanaem T, Kume E, Iwasaki H, Iida A, Shiraki-iida T, Nishikawa S, Nagai R, Nabeshima Y (1997) Mutation of the mouse klotho gene leads to a syndrome resembling aging. Nature 390:45–51. doi:10.1038/36285 PubMedCrossRef

52.

Ogata N, Matsumura Y, Shiraki M, Kawano K, Koshizuka Y, Hosoi T, Nakamura K, Kuro-o M, Kawaguchi H (2002) Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women. Bone 31:37–41. doi:10.1016/S8756-3282(02)00786-X PubMedCrossRef

53.

Tsuruoka S, Nishi K, Ioka T, Ando H, Saito Y, Kurabayashi M, Nagai R, Fujimora A (2006) Defect in parathyroid hormone induced luminal calcium absorption in connecting tubules of klotho mice. Nephrol Dial Transplant 21:2762–2767PubMedCrossRef

54.

Chang Q, Hoefs S, ven der Kemp AW, Topala AW, Bindels RJ, Hoenderop JG (2005) The beta glucoronidase klotho hydrolyzes and activates TRPV5 channel. Science 310:490–493. doi:10.1126/science.1114245 PubMedCrossRef

55.

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M (2006) Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 281:6120–6123. doi:10.1074/jbc.C500457200 PubMedCrossRef

56.

Marengo SR, Romani AMP (2008) Oxalate in renal stone disease: the terminal metabolite that just won’t go away. Nat Clin Pract Nephrol 4:368–377PubMedCrossRef

57.

Danpure CJ, Rumsby G (1995) Enzymology and molecular genetics of primary hyperoxaluria type 1, consequences for clinical management. In: Khan SR (ed) Calcium oxalate in biological systems. CRC Press Inc, Boca Raton, pp 189–205

58.

Cramer SD, Ferree PM, Lin K, Milliner DS, Holmes RP (1999) The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet 8:2063–2069. doi:10.1093/hmg/8.11.2063 PubMedCrossRef

59.

Salido EC, Li XM, Lu Y, Wang X, Santana A, Roy-Chowdhury N, Torres A, Shapiro LJ, Roy-Chowdhury J (2006) Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc Natl Acad Sci USA 103:18249–18254. doi:10.1073/pnas.0607218103 PubMedCrossRef

60.

Alper SL (2003) Diseases of mutations in the SLC4A1/AE1 (band 3) Cl–/HCO3–exchanger. In: Broer S, Wagner CA (eds) Membrane transporter diseases. Kluwer, New York, pp 39–63

61.

Stehberger PA, Shmukler BE, Stuart-Tilley AK, Peters LL, Alper SL, Wagner CA (2007) Distal renal tubular acidosis in mice lacking the AE1 (band3) Cl⁻/HCO₃-exchanger (slc4a1). J Am Soc Nephrol 18:1408–1418. doi:10.1681/ASN.2006101072 PubMedCrossRef

62.

Knight J, Holmes RP, Assimos DG (2007) Intestinal and renal handling of oxalate loads in normal individuals and stone formers. Urol Res 35:111–117. doi:10.1007/s00240-007-0090-8 PubMedCrossRef

63.

Krishnamurthy M, Hruska KA, Chandhoke PS (2003) The urinary response to an oral oxalate load in recurrent calcium stone formers. J Urol 169:2030–2035. doi:10.1097/01.ju.0000062527.37579.49 PubMedCrossRef

64.

Hatch M, Freel RW (2005) Intestinal transport of an obdurate anion: oxalate. Urol Res 33:1–16. doi:10.1007/s00240-004-0445-3 PubMedCrossRef

65.

Mount DB, Romero MF (2004) The SLC26 gene family of multifunctional anion exchangers. Pflugers Arch 447:710–721. doi:10.1007/s00424-003-1090-3 PubMedCrossRef

66.

Soleimani M (2006) Expression, regulation and the role of SLC26 Cl−/HCO₃–exchangers in kidney and gastrointestinal tract. Novartis Found Symp 273:91–102. doi:10.1002/0470029579.ch7 PubMedCrossRef

67.

Soleimani M, Xu J (2006) SLC26 chloride/nase exchangers in the kidney in health and disease. Semin Nephrol 26:375–385. doi:10.1016/j.semnephrol.2006.07.005 PubMedCrossRef

68.

Xie Q, Welch R, Mercado A, Romero MF, Mount DB (2002) Molecular characterization of the murine Slc26a6 anion exchanger: functional comparison with Slc26a1. Am J Physiol Renal Physiol 283:F826–F838PubMed

69.

Wang Z, Wang T, Petrovic S, Tuo B, Riederer B, Barone S, Lorenz JN, Seidler U, Aronson PS, Soleimani M (2005) Renal and intestinal transport defects in Slc26a6-null mice. Am J Physiol Cell Physiol 288:C957–C965. doi:10.1152/ajpcell.00505.2004 PubMedCrossRef

70.

Freel RW, Hatch M, Green M, Soleimani M (2006) Ileal oxalate absorption and urinary oxalate excretion are enhanced in Slc26a6 null mice. Am J Physiol 290:G719–G728

71.

Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, Binder HJ, Aronson PS (2006) Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet 38:474–478. doi:10.1038/ng1762 PubMedCrossRef

72.

Parks JH, Ruml LA, Pak CYC (1996) Hypocitraturia. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott, Philadelphia, pp 905–920

73.

Meyer JL, Smith LH (1975) Growth of calcium oxalate crystals II: inhibition by natural urinary crystal growth inhibitors. Invest Urol 13:36–39PubMed

74.

Pak CY, Nicar M, Northcutt C (1982) The definition of the mechanism of hypercalciuria is necessary for the treatment of recurrent stone formers. Contrib Nephrol 33:136–151PubMed

75.

Shah O, Assimos DG, Holmes RP (2005) Genetic and dietary factors in urinary citrate excretion. J Endourol 19:177–182. doi:10.1089/end.2005.19.177 PubMedCrossRef

76.

Pak CY (1987) Citrate and renal calculi. Miner Electrolyte Metab 13:257–266PubMed

77.

Hamm LL, Alpern RJ (1996) Regulation of acid–base balance, citrate, and urine pH. In: Coe FL, Favus MJ, Pak CYC, Parks JH, Preminger GM (eds) Kidney stones: medical and surgical management. Lippincott, Philadelphia, pp 289–302

78.

Hamm LL, Hering-Smith KS (2002) Pathophysiology of hypocitraturic nephrolithiasis. Endocrinol Metab Clin North Am 31:885–893. doi:10.1016/S0889-8529(02)00031-2 PubMedCrossRef

79.

Pajor AM (2001) Conformationally sensitive residues in transmembrane domain 9 of the Na+/dicarboxylate co-transporter. J Biol Chem 276:29961–29968. doi:10.1074/jbc.M011387200 PubMedCrossRef

80.

Okamoto N, Aruga S, Matsuzaki S, Takahashi S, Matsushita K, Kitamura T (2007) Associations between renal sodium-citrate co-transporter (hNaDC-1) gene polymorphism and urinary citrate excretion in recurrent renal calcium stone formers and normal controls. Int J Urol 14:344–349. doi:10.1111/j.1442-2042.2007.01554.x PubMedCrossRef

81.

He Y, Chen X, Yu Z, Wu D, Lv Y, Shi S, Zhu H (2004) Sodium dicarboxylate cotransporter-1 expression in renal tissues and its role in rat experimental nephrolithiasis. J Nephrol 17:34–42PubMed

82.

Kok DJ, Papapoulos SE, Blomen LMJ, Bijvoet OLM (1988) Modulation of calcium-oxalate monohydrate crystallization kinetics in vitro. Kidney Int 34:346–350. doi:10.1038/ki.1988.187 PubMedCrossRef

83.

Ryall RL, Harnett RM, Marshall VR (1988) The effect of urine, pyrophosphate, citrate, magnesium and glycosaminoglycans on the growth and aggregation of calcium oxalate crystals in vitro. Clin Chim Acta 112:349–356. doi:10.1016/0009-8981(81)90458-7 CrossRef

84.

Schwille PO, Rumenapf G, Wolfel G, Kohler R (1988) Urinary pyrophosphate in patients with recurrent urolithiasis and in healthy controls: a reevaluation. J Urol 140:239–245PubMed

85.

Sidhu H, Gupta R, Thind SK, Nath R (1986) Inhibition of calcium oxalate monohydrate crystal growth by pyrophosphate, citrate and rat urine. Urol Res 14:299–303. doi:10.1007/BF00262379 PubMedCrossRef

86.

Achilles W, Coors D, Reifenberger B, Sallis JD, Schalk CH (1989) Natural and artificial substances as inhibitors of crystal growth of calcium oxalates in gel matrices. In: Vahlensieck W, Gasser G, Hesse A, Schoeneich G (eds) Urolithiasis, proceedings 1st European symposium on urolithiasis, Bonn. Excerpta Medica, Amsterdam. ISBN 90 219 9865 3, pp 65–67

87.

Grases F, Ramis M, Costa-Bauza A (2000) Effects of phytate and pyrophosphate on brushite and hydroxyapatite crystallization—comparison with the action of other polyphosphates. Urol Res 28:136–140. doi:10.1007/s002400050152 PubMedCrossRef

88.

Robertson WG (1973) Factors affecting the precipitation of calcium phosphate in vitro. Calcif Tissue Res 11:311–322. doi:10.1007/BF02547230 PubMedCrossRef

89.

Laminski NA, Meyers AM, Sonnekus MI, Smyth AE (1990) Prevalence of hypocitraturia and hypopyrophosphaturia in recurrent calcium stone formers: as isolated defects or associated with other metabolic abnormalities. Nephron 56:379–384. doi:10.1159/000186179 PubMedCrossRef

90.

Tsui HW, Inman RD, Paterson AD, Reveille JD, Tsui FW (2005) ANKH variant is associated with ankylosing spondylitis: gender differences. Arthritis Res Ther 7:R513–R525. doi:10.1186/ar1701 PubMedCrossRef

91.

Canales BK, Leonard SM, Singh JS, Orzano IM, Zimmerman B, Weiland D, Monga M, Krug HS (2006) Spondyloarthropathy: an independent risk factor for kidney stones. J Endourol 20:542–546. doi:10.1089/end.2006.20.542 PubMedCrossRef

92.

Korkmaz C, Ozcan A, Akcar N (2005) Increased frequency of ultrasonographic findings suggestive of renal stone patients with ankylosing spondylitis. Clin Exp Rheumatol 23:389–392PubMed

93.

Min W, Sgiraga H, Chalko C, Goldfarb S, Krishna GG, Hoyer JR (1998) Quantitative studies of human urinary excretion of uropontin. Kidney Int 53:189–193. doi:10.1046/j.1523-1755.1998.00745.x PubMedCrossRef

94.

Nishio S, Hatanaka M, Takeda H, Iseda T, Iwata H, Yokoyama M (1999) Analysis of urinary concentrations of calcium phosphate crystal-associated proteins: alpha-2-HS-glycoprotein, prothrombin F1, and osteopontin. J Am Soc Nephrol 10:S394–S396PubMed

95.

Wesson JA, Johnson RJ, Mazzali M, Beshensky AM, Steitz S, Giachelli C, Liaw L, Alpers CE, Couser WG, Kleinman JG, Hughes J (2003) Osteopontin is acritical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J Am Soc Nephrol 14:139–147. doi:10.1097/01.ASN.0000040593.93815.9D PubMedCrossRef

96.

Gao B, Yasui T, Itoh Y, Li Z, Okada A, Tozawa K, Hayashi Y, Kohri K (2007) Association of osteopontin gene haplotypes with nephrolithiasis. Kidney Int 72:592–598. doi:10.1038/sj.ki.5002345 PubMedCrossRef

97.

Fisher LW, Hawkins GR, Tuross N, Termine JD (1987) Purification and partial characterization of small proteoglycans I and II, bone sialoproteins I and II, and osteonectin from the mineral compartment of developing human bone. J Biol Chem 262:9702–9708PubMed

98.

Singh K, DeVouge MW, Mukherjee BB (1990) Physiological properties and differential glycosylation of phosphorylated and nonphosphorylated forms of osteopontin secreted by normal rat kidney cells. J Biol Chem 265:18696–18701PubMed

99.

Hunter GK, Kyle CL, Goldberg HA (1994) Modulation of crystal formation by bone phosphoproteins; structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 300:723–728PubMed

100.

Hoyer JR, Asplin JR, Otvos LJ (2001) Phosphorylated osteopontin peptides suppress crystallization by inhibiting growth of calcium oxalate crystals. Kidney Int 60:77–82. doi:10.1046/j.1523-1755.2001.00772.x PubMedCrossRef

101.

Atmani F, Glenton PA, Khan SR (1998) Identification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in the urine of healthy and stone forming subjects. Urol Res 26:201–207. doi:10.1007/s002400050047 PubMedCrossRef

102.

Glauser A, Horhreiter W, Jaeger P, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 15:158–1587. doi:10.1093/ndt/15.10.1580 CrossRef

103.

Romero MC, Nocera S, Nesse AB (1997) Decreased Tamm-Horsfall protein in lithiasis patients. Clin Biochem 30:63–67. doi:10.1016/S0009-9120(96)00136-1 PubMedCrossRef

104.

Schnierle P (1995) A simple diagnostic method for the differentiation of Tamm-Horsfall glycoprotein from healthy probands and those from recurrent calcium oxalate renal stone formers. Experimentia 51:1068–1072. doi:10.1007/BF01946918 CrossRef

105.

Mo L, Huang H-Y, Zhu X-H, Shapiro E, Hasty DL, X-Ru Wu (2004) Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. Kidney Int 66:1159–1166. doi:10.1111/j.1523-1755.2004.00867.x PubMedCrossRef

106.

Mo L, Liaw L, Evan AP, Sommer AJ, Lieske JC, Wu X-R (2007) Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Renal Physiol 293:F1935–F1943. doi:10.1152/ajprenal.00383.2007 PubMedCrossRef

107.

Bernascone I, Vavassori S, Di Pentima AD, Santambrogio S, Lamorte G, Amoroso A, Scolari F, Ghiggeri GM, Casari G, Polishchuk R, Rampoldi L (2006) Defective intracellular trafficking of uromodulin mutant isoforms. Traffic 7:1567–1579. doi:10.1111/j.1600-0854.2006.00481.x PubMedCrossRef

108.

Serafini-Cessi F, Maligolini N, Cavallone D (2003) Tamm-Horsfall protein glycoprotein: biology and clinical relevance. Am J Kidney Dis 42:658–676. doi:10.1016/S0272-6386(03)00829-1 PubMedCrossRef

109.

Biri H, Ozturk HS, Buyukkocak S, Kacmaz M, Cimen MYB, Unal D, Birey M, Bozkirli I, Durak I (1998) Antioxidant defense potential of rabbit renal tissues after ESWL: protective effects of antioxidant vitamins. Nephron 79:181–185. doi:10.1159/000045022 PubMedCrossRef

110.

Atmani F, Lacour B, Jungers P, Drüeke T, Daudon M (1994) Reduced inhibitory activity of uronic-acid-rich protein in urine of stone formers. Urol Res 22:257–260. doi:10.1007/BF00541903 PubMedCrossRef

111.

Suzuki S, Kobayashi H, Kageyama S, Shibata K, Fujie M, Terao T (2001) Excretion of bikunin and its fragments in the urine of patients with renal stones. J Urol 166:268–274. doi:10.1016/S0022-5347(05)66143-5 PubMedCrossRef

112.

Medetognon-Benissan J, Tardivel S, Hennequin C, Daudon T, Drueke T, Lacour B (1999) Inhibitory effect of bikunin on calcium oxalate crystallization in vitro and urinary bikunin decrease in renal stone formers. Urol Res 27:69–75. doi:10.1007/s002400050091 PubMedCrossRef

113.

Atmani F, Khan SR (1999) Role of urinary bikunin in the inhibition of calcium oxalate crystallization. J Am Soc Nephrol 10:S385–S390PubMed

114.

Atmani F, Mizon J, Khan SR (1996) Identification of uronic-acid-rich protein as urinary bikunin, the light chain of inter-α-inhibitor. Eur J Biochem 236:984–990. doi:10.1111/j.1432-1033.1996.00984.x PubMedCrossRef

115.

Ebisuno S, Nishihata M, Inagaki T, Umehara M, Kohjimoto Y (1999) Bikunin prevents adhesion of CaOx crystal to renal tubular cells in human urine. J Am Soc Nephrol 10:S436PubMed

116.

Tardivel S, Medetognon J, Randoux C, Kebede M, Drueke T, Daudon M, Hennequin C, Lacour B (1999) Alpha-1-microglobulin: inhibitory effect on calcium oxalate crystallization in vitro and decreased urinary concentration in calcium oxalate stone formers. Urol Res 27:243–249. doi:10.1007/s002400050117 PubMedCrossRef

117.

Khan SR (2005) Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 33:349–357. doi:10.1007/s00240-005-0492-4 PubMedCrossRef

Titel: Genetic basis of renal cellular dysfunction and the formation of kidney stones
verfasst von: Saeed R. Khan
Benjamin K. Canales
Publikationsdatum: 01.08.2009
Verlag: Springer-Verlag
Erschienen in: Urolithiasis / Ausgabe 4/2009
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI: https://doi.org/10.1007/s00240-009-0201-9

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Genetic basis of renal cellular dysfunction and the formation of kidney stones

Abstract

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Update Urologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Perforation of hollow viscera as a result of lithotripsy caused by shock waves: why does this occur?

Studies on the role of calcium phosphate in the process of calcium oxalate crystal formation

Ureteral stones due to systemic mastocytosis: diagnostic and therapeutic characteristics

Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis

Regional and seasonal variation in the incidence of urolithiasis in Iran: a place for obsession in case finding and statistical approach

Which efficiency index for urinary stones treatment?

Neu im Fachgebiet Urologie

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Update Urologie